Align Technology Stock (US0162551016): Reports Q1 2026 Results with 2% Revenue Decline

Align Technology Inc. released first-quarter 2026 results on April 29, showing $956.7 million in revenue, down 2% year-over-year amid softer demand in North America. The Nasdaq-listed company reaffirmed full-year guidance, trading at $219.18 as of April 30, 2026, 9:00 a.m. ET.

Align Technology Inc. published its first-quarter 2026 financial results on April 29, 2026, according to the company release dated 04/29/2026. Revenue fell to $956.7 million from $977.8 million in the year-ago quarter, reflecting a 2% decline on a reported basis and flat as-reported constant currency.

As of: April 30, 2026

By the AD HOC NEWS Editorial Team – Equity desk for medtech stocks.

At a glance

• Name: Align Technology Inc.
• ISIN: US0162551016
• Sector/Industry: Health Care Equipment & Supplies
• Headquarters/Country: Tempe, Arizona, USA
• Key markets: North America, EMEA, APAC
• Main revenue drivers: Invisalign clear aligners, iTero scanners
• Primary exchange/trading venue: Nasdaq (ALGN)
• Trading currency: USD
• CEO: Joseph M. Hogan
• Latest quarterly results: Q1 2026 revenue $956.7M (published 04/29/2026)

Align Technology's business model in brief

Align Technology develops and markets Invisalign clear aligner systems for orthodontic treatment, alongside intraoral scanning solutions via iTero scanners. The company operates a direct-to-consumer model for aligners in many markets, with cases shipped globally from manufacturing sites in Mexico, China, and the U.S. Nasdaq listing provides U.S. investors direct access via standard brokerage accounts.

Invisalign volumes reached 593,000 cases in Q1 2026, per the company release dated 04/29/2026. iTero scanner placements totaled 74, up 18% year-over-year, supporting digital workflows for orthodontists and general practitioners.

Key revenue and product drivers for Align Technology

Clear Aligner revenue comprised $809.2 million in Q1 2026, down 4% year-over-year, according to the company release dated 04/29/2026. North America saw a 15% drop to $407 million due to normalized post-COVID demand, while International Aligners grew 7% to $402.2 million.

Systems and Services revenue hit $147.5 million, up 13%, driven by iTero scanner growth. Non-case revenue increased 20% to $214.5 million, reflecting services and scanners. The company reaffirmed 2026 guidance for 585,000 to 625,000 Invisalign cases and $4.0 billion to $4.1 billion in total revenue.

Industry trends and competitive position

The clear aligner market continues expanding, with Align holding dominant share through Invisalign's brand and ecosystem. Digital orthodontics benefits from rising adult adoption and teen volumes, which grew 64% year-over-year to 84,000 cases in Q1.

Why Align Technology matters for U.S. investors

As a Nasdaq-100 component trading in USD, Align Technology offers U.S. retail investors exposure to medtech innovation without FX risk. Over 40% of revenue derives from North America, tying performance to domestic consumer dental spending amid inflation pressures.

SEC filings provide transparency, with Q1 results filed via Form 10-Q. ETF inclusion in health care funds like IHI enhances portfolio accessibility.

The stock traded at $219.18 on 04/30/2026 at 9:00 a.m. ET on Nasdaq, according to Nasdaq.com on 04/30/2026, 9:00 a.m. ET, down 1.2% from the previous close on 04/29/2026.

Which type of investor may follow Align Technology stock — and who may not?

Growth-oriented investors tracking medtech may monitor Align for Invisalign volume trends and scanner recurring revenue. Those focused on recurring SaaS-like models in health care could find alignment with iTero services.

Short-term traders sensitive to quarterly demand fluctuations in elective procedures may observe less stability compared to essential medtech peers.

Risks and open questions for Align Technology

Regional softness in North America persists, with volumes down 10% year-over-year in Q1. Macroeconomic factors like higher interest rates could further pressure elective orthodontic spending.

Competition from direct-to-consumer aligner providers remains, though Align's professional channel dominance provides a moat.

What investors may watch next

Upcoming watch points

• Q2 2026 earnings: Scheduled for late July 2026
• Invisalign Teen volumes: Summer seasonality

Investors may track Q2 Invisalign case starts and teen segment momentum into summer, per historical patterns noted in the company release dated 04/29/2026.

Bottom line

Align Technology's Q1 2026 results highlighted regional challenges in North America offset by international growth and iTero strength, as detailed in the April 29 release. Guidance stability supports monitoring volume recovery amid U.S. market dynamics.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.